MARKET

CTIC

CTIC

Cti Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.31
+0.14
+2.61%
Opening 13:26 05/25 EDT
OPEN
5.16
PREV CLOSE
5.17
HIGH
5.42
LOW
5.07
VOLUME
2.26M
TURNOVER
5.57M
52 WEEK HIGH
5.76
52 WEEK LOW
1.430
MARKET CAP
578.07M
P/E (TTM)
-4.3501
1D
5D
1M
3M
1Y
5Y
INO, WWR and CTIC among pre market gainers
GeoVax Labs (GOVX) +20%. Inovio Pharmaceuticals (INO) +19%. SIGA Technologies (SIGA) +15% Monkeypox plays indicate further upside as global toll climbs. O2Micro International (OIIM) +13%. GoldMining (GLDG) +12%. Emergent BioSolutions (EBS) +12% Monkeypox p...
Seekingalpha · 2d ago
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Decisionpoint Systems, Inc. (NASDAQ: DPSI) rose 47.2% to $7.02 in pre-market trading after jumping around 19% on Tuesday. DecisionPoint Systems recently reported first-quarter FY22 revenue growth of 22.7% year-on-year to $19.7 million.
Benzinga · 05/18 10:06
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 21:45
CTI BioPharma Q1 EPS $(0.37) Beats $(0.41) Estimate, Sales $2.29M Beat $1.54M Estimate
CTI BioPharma (NASDAQ:CTIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 60.87 percent decrease over losses of $(0.23) per share from the
Benzinga · 05/12 21:32
CTI BioPharma GAAP EPS of -$0.37 beats by $0.04, revenue of $2.3M beats by $0.76M
CTI BioPharma press release (NASDAQ:CTIC): Q1 GAAP EPS of -$0.37 beats by $0.04. Revenue of $2.3M beats by $0.76M. As of March 31, 2022, our cash and cash equivalents totaled
Seekingalpha · 05/12 20:08
CTI BioPharma Q1 2022 Earnings Preview
CTI BioPharma (NASDAQ:CTIC) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.41 (-78.3% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/11 21:35
CPNG, HIVE and CLSK among pre market gainers
Biohaven Pharmaceutical BHVN +72% on Q1 results. Evaxion Biotech (EVAX) +54% announces successful production of personalized cancer immunotherapies in phase 1/2a clinical trial for EVX-02. Vroom VRM +36% on Q1 results. Vertex Energy VTNR +16% on Q1
Seekingalpha · 05/10 12:31
More
No Data
Learn about the latest financial forecast of CTIC. Analyze the recent business situations of Cti Biopharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTIC stock price target is 9.53 with a high estimate of 15.00 and a low estimate of 6.00.
High15.00
Average9.53
Low6.00
Current 5.32
EPS
Actual
Estimate
-0.33-0.25-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 125
Institutional Holdings: 60.64M
% Owned: 55.65%
Shares Outstanding: 108.97M
TypeInstitutionsShares
Increased
24
15.12M
New
31
6.88M
Decreased
18
7.87M
Sold Out
3
2.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.52%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
Laurent Fischer
President/Chief Executive Officer/Director
Adam Craig
Chief Financial Officer/Executive Vice President/Secretary
David Kirske
Chief Operating Officer/Executive Vice President
Bruce Seeley
Senior Vice President
James Fong
Non-Executive Independent Director
Michael Metzger
Non-Executive Independent Director
David Parkinson
Non-Executive Independent Director
Diane Parks
Non-Executive Independent Director
Matthew Perry
Non-Executive Independent Director
Reed Tuckson
No Data
No Data
About CTIC
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.